8-溴-2-三氟甲基咪唑并[1,2-a]吡嗪 | 850406-42-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡嗪类
• 中文名称: 8-溴-2-三氟甲基咪唑并[1,2-a]吡嗪
• 英文名称: 8-bromo-2-(trifluoromethyl)imidazo[1,2-a]pyrazine
• 英文别名: 8-bromo-2-trifluoromethyl-imidazo[1,2-a]pyrazine；8-Bromo-2-(trifluoromethyl)imidazo[1,2-a]pyrazine
• CAS: 850406-42-7
• 化学式: C₇H₃BrF₃N₃
• 分子量: 266.02
• InChiKey: RTGNCNIUQPMHTL-UHFFFAOYSA-N

物化性质

• 密度：
  1.96±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-氨基-3-溴吡嗪 、 3-溴-1,1,1-三氟丙酮 以 乙二醇二甲醚 为溶剂， 反应 4.0h， 以25%的产率得到8-溴-2-三氟甲基咪唑并[1,2-a]吡嗪
  参考文献：
  名称：

  [EN] SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS
  [FR] COMPOSÉS TÉTRAHYDROQUINOLINONE SUBSTITUÉS EN TANT QUE MODULATEURS DE ROR GAMMA

  摘要：

  本发明提供了公式（I）的取代四氢喹啉酮及相关化合物，作为视黄酸受体相关孤儿受体（RORs）的调节剂，在RORγ调节剂方面具有治疗上的用途。这些化合物在治疗和预防疾病和/或紊乱方面具有用途，特别是它们在由RORγ受体介导的疾病和/或紊乱中的用途。本发明还提供了这些化合物的制备以及包含至少一种取代四氢喹啉酮或相关化合物的制剂和药物配方，以及其所用的药学上可接受的载体、稀释剂或赋形剂。

  公开号：

  WO2016185342A1

文献信息

• METHOD FOR THE PREPARATION OF TETRAHYDROQUINOLINONE COMPOUNDS HAVING ROR-GAMMA MODULATING ACTIVITY
  申请人：Aurigene Discovery Technologies Limited

  公开号：EP3845526A1

  公开（公告）日：2021-07-07

  The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORy modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了取代的四氢喹啉酮和相关的式(I)化合物，它们作为视黄酸受体相关孤儿受体（RORs）的调节剂，特别是作为RORy调节剂，具有治疗作用。这些化合物可用于治疗和预防疾病和/或失调，特别是用于 RORγ 受体介导的疾病和/或失调。本发明还提供了包含至少一种取代的四氢喹啉酮或式（I）相关化合物的化合物和药物制剂的制备方法，以及药学上可接受的载体、稀释剂或赋形剂。
• Substituted tetrahydroquinolinone compounds as ROR gamma modulators
  申请人：Aurigene Discovery Technologies Limited

  公开号：US11229636B2

  公开（公告）日：2022-01-25

  The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

  本发明提供了取代的四氢喹啉酮和相关的式(I)化合物，它们作为视黄酸受体相关孤儿受体（RORs）的调节剂，特别是作为RORγ调节剂，具有治疗作用。这些化合物可用于治疗和预防疾病和/或紊乱，特别是用于治疗由 RORγ 受体介导的疾病和/或紊乱。本发明还提供了包含至少一种取代的四氢喹啉酮或式（I）相关化合物的化合物和药物制剂的制备方法，以及药学上可接受的载体、稀释剂或赋形剂。
• [EN] 7H-IMIDAZO [1,2-alpha] PYRAZIN-8-ONE COMPOUNDS AS ION CHANNEL MODULATORS<br/>[FR] COMPOSÉS À STRUCTURE IMIDAZO ET LEURS UTILISATIONS
  申请人：CARDIOME PHARMA CORP

  公开号：WO2005034837A3

  公开（公告）日：2005-07-14
• SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS
  申请人：Aurigene Discovery Technologies Limited

  公开号：EP3294713A1

  公开（公告）日：2018-03-21
• Substituted Tetrahydroquinolinone Compounds as ROR Gamma Modulators
  申请人：Aurigene Discovery Technologies Limited

  公开号：US20180200247A1

  公开（公告）日：2018-07-19

  The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as RORγ modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by RORγ receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.